Urteste S.A. (WSE:URT)

Poland flag Poland · Delayed Price · Currency is PLN
51.60
-1.80 (-3.37%)
Feb 12, 2026, 5:00 PM CET
Market Cap72.74M -45.7%
Revenue (ttm)1.80M +42.9%
Net Income-5.47M
EPS-3.88
Shares Out1.41M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,011
Average Volume991
Open53.20
Previous Close53.40
Day's Range49.00 - 53.20
52-Week Range24.00 - 92.00
Beta0.13
RSI48.92
Earnings DateApr 29, 2026

About Urteste

Urteste S.A. engages in the research and development of diagnostic tests for cancers. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, bile ducts, stomach, lung, esophagus, ovary, endometrium, blood, breast, and brain. The company was incorporated in 2021 and is based in Gdańsk, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Employees 36
Stock Exchange Warsaw Stock Exchange
Ticker Symbol URT
Full Company Profile

Financial Performance

In 2024, Urteste's revenue was 1.80 million, an increase of 35.34% compared to the previous year's 1.33 million. Losses were -3.63 million, -35.00% less than in 2023.

Financial Statements